Research Articles | Page 96 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Alternative donor HSCT in refractory acquired aplastic anemia: The time has come May 2012 Pediatr Transplant aplastic anemia
Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation Mar 2012 Pediatr Transplant aplastic anemia
Less could be better: The case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia. Apr 2013 Pediatr Transplant aplastic anemia
Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia. Apr 2013 Pediatr Transplant aplastic anemia
A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the Nort Aug 2020 Pediatric Blood & Cancer aplastic anemia, pediatric
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium Aug 2020 Pediatric Blood & Cancer aplastic anemia, myelodysplastic syndromes (MDS), pediatric
Eltrombopag in children with severe aplastic anemia Apr 2021 Pediatric Blood & Cancer aplastic anemia, pediatric
Cotransplantation of allogeneic mesenchymal and hematopoietic stem cells in children with aplastic anemia May 2012 Pediatrics aplastic anemia
The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes Jan 2012 PLoS One myelodysplastic syndromes (MDS)
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. Sep 2020 PloS One paroxysmal nocturnal hemoglobinuria (PNH)
Share with addtoany.com.